Douglas Wisniewski
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Immune Response and Inflammation, Fungal and yeast genetics research, RNA Research and Splicing, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy(2017)331 cited
- → Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein(2007)224 cited
- → Anthrax lethal factor inhibition(2005)176 cited
- → A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S](2010)133 cited
- → In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa(2019)121 cited
- → A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake(2010)107 cited
- → The nuclear membrane organization of leukotriene synthesis(2008)104 cited
- → An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes(2012)103 cited
- → A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease(2002)96 cited
- → The membrane organization of leukotriene synthesis(2004)95 cited